The 2012 garrod lecture: Discovery of antibacterial drugs in the 21st century

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 3, 2013, Pages 496-505

  Chopra, Ian ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Antibiotics; Screening; Structure based design; Targets

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; ANTIINFECTIVE AGENT; BACTERIAL RNA; NATURAL PRODUCT; PEPTIDE DEFORMYLASE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACILLUS SUBTILIS; BIOSENSOR; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; DNA MICROARRAY; DRUG ACCUMULATION; DRUG BINDING SITE; DRUG DESIGN; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; FATTY ACID SYNTHESIS; GENE SEQUENCE; GENOMICS; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNTHESIS;

ANTI-BACTERIAL AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; HUMANS;

EID: 84873601555     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks436     Document Type: Article

References (49)

1. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011; 24: 71-109.
2. von Nussbaum F, Brands M, Hinzen B et al. Antibacterial natural products in medicinal chemistry-exodus or revival? Angew Chem Int Ed 2006; 45: 5072-129.
3. White AR. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control. J Antimicrob Chemother 2011; 66: 1948-53.
4. Piddock LJV. The crisis of no new antibiotics-what is the way forward? Lancet Infect Dis 2012; 12: 249-53.
5. Yoshikawa TT. Antimicrobial resistance and aging: beginning of the end of the antibiotic era? J Am Geriatr Soc 2002; 50: S206-9.
6. Appelbaum PC. 2012 and beyond: potential for the start of a second pre-antibiotic era? J Antimicrob Chemother 2012; 67: 2062-8.
7. Infectious Diseases Society of America. Antibiotic development: the 10×20 initiative. http://www.idsociety.org/10×20 (13 August, date last accessed).
8. Cars O, Hedin A, Heddini A. The global need for effective antibiotics- moving towards concerted action. Drug Resist Updat 2011; 14: 68-9.
9. Alvan G, Edlund C, Heddini A. The global need for effective antibiotics- a summary of plenary presentations. Drug Resist Updat 2011; 14: 70-6.
10. Wise R. The urgent need for new antibacterial agents. J Antimicrob Chemother 2011; 66: 1939-40.
11. Antibiotic Action homepage. http://antibiotic-action.com (13 August, date last accessed).
12. Innovative Medicines Initiative. Partnersearch. http://www.imi.europa.eu (13 August date last accessed).
13. Finch R. Regulatory opportunities to encourage technology solutions to antibacterial drug resistance. J Antimicrob Chemother 2011; 66: 1945-7.
14. Payne DJ, Gwynn MN, Holmes DJ et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007; 6: 29-40.
15. Gwynn MN, Portnoy A, Rittenhouse SF et al. Challenges of antibacterial discovery revisited. Ann N Y Acad Sci 2010; 1213: 5-19.
16. Livermore DM. Discovery research: the scientific challenge of finding new antibiotics. J Antimicrob Chemother 2011; 66: 1941-4.
17. Simmons KJ, Chopra I, Fishwick CWG. Structure-based discovery of antibacterial drugs. Nat Rev Microbiol 2010; 8: 501-10.
18. Chopra I, Hodgson J, Metcalf B et al. The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics. Antimicrob Agents Chemother 1997; 41: 497-503.
19. Jones D. The antibacterial lead discovery challenge. Nat Rev Drug Discov 2010; 9: 751-2.
20. Lewis K. Recover the lost art of drug discovery. Nature 2012; 485: 439-40.
21. Spratt BG. Resistance to antibiotics mediated by target alterations. Science 1994; 264: 388-93.
22. Mariner KR, Ooi N, Roebuck D et al. Further characterization of Bacillus subtilis antibiotic biosensors and their use for antibacterial mode-of-action studies. Antimicrob Agents Chemother 2011; 55: 1784-6.
23. O'Neill AJ, Chopra I. Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques. Exp Opin Invest Drugs 2004; 13: 1045-63.
24. O'Shea R, Moser HE. Physiochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem 2008; 51: 2871-8.
25. Agarwal AK, Fishwick CWG. Structure-based design of anti-infectives. Ann N Y Acad Sci 2010; 1213: 20-45.
26. McPhillie MJ, Trowbridge R, Mariner KR et al. Structure-based ligand design of novel bacterial RNA polymerase inhibitors. ACS Med Chem Lett 2011; 2: 729-34.
27. Chopra I. Bacterial RNA polymerase: a promising target for the discovery of new antimicrobial agents. Curr Opin Invest Drugs 2007; 8: 600-7.
28. Belogurov GA, Vassylyeva MN, Sevostyanova A et al. Transcription inactivation through local refolding of the RNA polymerase structure. Nature 2009; 457: 332-5.
29. Moy TI, Daniel A, Hardy C et al. Evaluating the activity of the RNA polymerase inhibitor myxopyronin B against Staphylococcus aureus. FEMS Microbiol Lett 2011; 319: 176-9.
30. Mochalkin I, Miller JR, Narasimhan L et al. Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches. ACS Chem Biol 2009; 4: 473-83.
31. Choi JY, Plummer MS, Starr J et al. Structure guided development of novel thymidine mimetics targeting Pseudomonas aeruginosa thymidylate kinase: from hit to lead generation. J Med Chem 2012; 55: 852-70.
32. Hwang J, Tseitin V, Ramnarayan K et al. Structure-based design and screening of inhibitors for an essential bacterial GTPase, Der. J Antibiot 2012; 65: 237-43.
33. Venturelli A, Tondi D, Cancian L et al. Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy. J Med Chem 2007; 50: 5644-54.
34. Wencewicz TA, Mollmann U, Long TE et al. Is drug release necessary for antimicrobial activity of siderophore-drug conjugates? Synthesis and biological studies of the naturally occurring salmycin 'Trojan Horse' antibiotics and synthetic desferridanoxamine-antibiotic conjugates. Biometals 2009; 22: 633-48.
35. Miethke M, Marahiel MA. Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev 2007; 71: 413-51.
36. Zoeiby AE, Sanschagrin F, Levesque RC. Structure and function of the Mur enzymes: development of novel inhibitors. Mol Microbiol 2003; 47: 1-12.
37. Smith CA. Structure, function and dynamics in the mur family of bacterial cell wall ligases. J Mol Biol 2006; 362: 640-55.
38. Bugg TDH, Braddick D, Dowson CG et al. Bacterial cell wall assembly: still an attractive antibacterial target. Trends Biotechnol 2011; 29: 167-73.
39. Mariner KR, Trowbridge R, Agarwal AK et al. Furanyl-rhodanines are unattractive drug candidates for development as inhibitors of bacterial RNA polymerase. Antimicrob Agents Chemother 2010; 54: 4506-9.
40. Silver LL. Does the cell wall of bacteria remain a viable source of targets for novel antibiotics? Biochem Pharmacol 2006; 71: 996-1005.
41. White CL, Kitch A, Gober JW. Positioning cell wall synthetic complexes by the bacterial morphogenetic proteins MreB and MreD. Mol Microbiol 2010; 76: 616-33.
42. Newman DJ, Cragg GM, Snader KM. The influence of natural products upon drug discovery. Nat Prod Rep 2000; 17: 215-34.
43. Banik JJ, Brady SF. Recent application of metagenomic approaches toward the discovery of antimicrobials and other bioactive small molecules. Curr Opin Microbiol 2010; 13: 603-9.
44. Piel J. Approaches to capturing and designing biologically active small molecules produced by uncultured microbes. Annu Rev Microbiol 2011; 65: 431-53.
45. Woodford N, Wareham DW. Tackling antibiotic resistance: a dose of common antisense? J Antimicrob Chemother 2009; 63: 225-9.
46. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009; 64: Suppl I: i29-36.
47. Butler MS, Cooper MA. Antibiotics in the clinical pipeline in 2011. J Antibiot 2011; 64: 413-25.
48. Whiley DM, Goire N, Lahra MM et al. The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting. J Antimicrob Chemother 2012; 67: 2059-61.
49. McDermott WM, Rogers DE. Social ramifications of control of microbial disease. Johns Hopkins Med J 1982; 151: 302-12.